Welcome to our dedicated page for Ardelyx news (Ticker: ARDX), a resource for investors and traders seeking the latest updates and insights on Ardelyx stock.
Ardelyx, Inc. develops and commercializes biopharmaceutical products built around tenapanor and NHE3 inhibition. The company has two U.S.-approved commercial products: IBSRELA for adults with irritable bowel syndrome with constipation and XPHOZAH to reduce serum phosphorus in adults with chronic kidney disease on dialysis when phosphate binder therapy is inadequate or not tolerated.
Ardelyx news commonly covers product revenue, prescription trends, business updates, scientific meeting presentations, and clinical analyses tied to XPHOZAH and IBSRELA. Recurring developments also include pipeline work in chronic idiopathic constipation and next-generation NHE3 inhibition, commercialization with partners outside the United States, patient advocacy programs, and executive leadership changes in medical, legal, finance, and compliance functions.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Ardelyx, Inc. (Nasdaq: ARDX) has announced the granting of stock options and Restricted Stock Units (RSUs) to new non-executive employees as employment inducements. On July 25, 2023, the company's compensation committee approved:
- Options to purchase 100,216 shares of common stock for three new employees
- 51,000 RSUs for four new employees
The stock options have an exercise price of $3.44 per share, matching the closing trading price on the grant date. Both stock options and RSUs vest over four years, with specific vesting schedules. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the company's 2016 Employment Commencement Incentive Plan.
Summary not available.
Summary not available.
Summary not available.
Summary not available.